BLAINTRAVENOUSINJECTABLE
Approved
Jun 2024
Lifecycle
Growth
Competitive Pressure
30/100
Clinical Trials
10
Data completeness
4/8 — Partial
PIASKY (crovalimab) by Roche is complement c5 inhibitors [moa]. Approved for complement c5 inhibitor [epc]. First approved in 2024.
Drug data last refreshed 18h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
PIASKY (crovalimab) is a monoclonal antibody complement C5 inhibitor approved in June 2024 for paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS). It blocks complement-mediated cell destruction, reducing hemolysis and organ damage in these rare, life-threatening conditions. The IV monoclonal antibody targets a well-validated pathway already occupied by established therapies.
Growth
Early-stage launch asset with limited current spending data; growth trajectory depends on uptake in crowded complement inhibitor space and clinical differentiation against entrenched competitors.
Mechanism of Action
Complement C5 Inhibitors
Pharmacologic Class:
Complement C5 Inhibitor
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (10)
A Study to Evaluate Crovalimab in People With Antiphospholipid Syndrome (APS)
Started Mar 2026
0Antiphospholipid Syndrome
A Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Crovalimab in Participants With Guillain-Barré Syndrome (GBS)
Started Nov 2022
0Guillain-Barré Syndrome
A Study Evaluating the Safety, Pharmacokinetics, Pharmacodynamics and Efficacy of Crovalimab for the Management of Acute Uncomplicated Vaso-Occlusive Episodes (VOE) in Participants With Sickle Cell Disease (SCD).
Started Mar 2022
30 enrolled
Sickle Cell Disease
A Study Evaluating the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Crovalimab as Adjunct Treatment in Prevention of Vaso-Occlusive Episodes (VOE) in Sickle Cell Disease (SCD)
Started Mar 2022
95 enrolled
Sickle Cell Disease
A Study Evaluating the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of Crovalimab in Pediatric Participants With Atypical Hemolytic Uremic Syndrome (aHUS)
Started Nov 2021
41 enrolled
Atypical Hemolytic Uremic Syndrome
Worked on PIASKY at Roche? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.